References

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

10.1200/jco.2005.05.2308 · 2006 · External reference

Chemotherapy for metastatic gastric cancer: past, present, and future

10.1007/s00535-008-2177-6 · 2008 · External reference

Esophageal cancer

10.1056/nejmra035010 · 2003 · External reference

Gastric adenocarcinoma: review and considerations for future directions

10.1097/01.sla.0000149300.28588.23 · 2005 · External reference

Early HER2 dysregulation in gastric and esophageal carcinogenesis

10.1111/j.1365-2559.2012.04272.x · 2012 · External reference

The ErbB receptors and their ligands in cancer: an overview

10.2174/1389450053765879 · 2005 · External reference

HER-2/neu (c-erb-B2) gene and protein in breast cancer

1999 · External reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

10.1056/nejm200103153441101 · 2001 · External reference

Localization of a novel v-erbB-related gene, c-erb B-2, on human chromosome 17 and its amplification in a gastric cancer cell line

1986 · External reference

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

10.1002/(sici)1097-0142(19990501)85:9<1894::aid-cncr3>3.0.co;2-j · 1999 · External reference

HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature

10.7150/jca.4090 · 2012 · External reference

Targeted HER2 treatment in advanced gastric cancer

10.1159/000288295 · 2010 · External reference

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus

10.1038/modpathol.3800712 · 2007 · External reference

Prognostic significance of expression patterns of c-erb B-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study

10.1136/jcp.2005.034298 · 2006 · External reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

10.1016/s0140-6736(10)61121-x · 2010 · External reference

Unresolved reference

2009 · External reference

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

10.1200/jco.2006.09.2775 · 2007 · External reference

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for HER-2 status in breast cancer

10.1186/1477-7819-7-83 · 2009 · External reference

Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens

10.1007/s12013-011-9286-1 · 2012 · External reference

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

10.1111/j.1365-2559.2008.03028.x · 2008 · External reference

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

10.1093/annonc/mdn169 · 2008 · External reference

A study of HER2 gene amplification and protein expression in gastric cancer

10.1136/jcp.2010.076570 · 2010 · External reference

Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections

10.1111/j.1365-2559.2011.04017.x · 2011 · External reference

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer

2006 · External reference

Unresolved reference

2010 · External reference

The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification

10.1111/apm.1965.64.1.31 · 1965 · External reference

Gastric carcinoma. A pathobiological classification

10.1002/1097-0142(197706)39:6<2475::aid-cncr2820390626>3.0.co;2-l · 1977 · External reference

Unresolved reference

2009 · External reference

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

10.1007/s00428-010-0952-2 · 2010 · External reference

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)

10.1111/j.1365-2559.2011.03760.x · 2011 · External reference

Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening program of the ToGA trial

10.1200/jco.2009.27.15_suppl.4556 · 2009 · External reference

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

10.1038/modpathol.3880154 · 2000 · External reference

HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series

2010 · External reference

Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

10.1111/j.1365-2559.2011.04012.x · 2011 · External reference

Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays

10.1245/s10434-011-1695-2 · 2011 · External reference

Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas

10.1097/pat.0b013e3283513e8b · 2012 · External reference